Biodesix, Inc.
Records under this name other than the patents Biodesix, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 39 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,593,529 | Mass-Spectral Method for Selection, and De-selection, of Cancer Patients for Treatment with Immune Response Generating Therapies now held by Globeimmune, Inc. In force · High confidence | In force | High confidence | |
| US 9,653,272 | Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment with Immune Response Generating Therapies now held by Globeimmune, Inc. In force · High confidence | In force | High confidence | |
| US 10,217,620 | Early Detection of Hepatocellular Carcinoma in High Risk Populations Using Maldi-Tof Mass Spectrometry In force · High confidence | In force | High confidence | |
| US 10,007,766 | Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods In force · High confidence | In force | High confidence | |
| US 10,037,874 | Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF Mass Spectrometry In force · High confidence | In force | High confidence | |
| US 7,858,389 | Selection of Non-Small-Cell Lung Cancer Patients for Treatment with Monoclonal Antibody Drugs Targeting Egfr Pathway Term ended Ended no later than Jun 2, 2026 · Medium confidence | Term ended | Ended no later than Jun 2, 2026 | Medium confidence |
| US 7,906,342 | Monitoring Treatment of Cancer Patients with Drugs Targeting Egfr Pathway Using Mass Spectrometry of Patient Samples Term ended Ended no later than May 27, 2026 · Medium confidence | Term ended | Ended no later than May 27, 2026 | Medium confidence |
| US 7,867,775 | Selection of Head and Neck Cancer Patients for Treatment with Drugs Targeting Egfr Pathway Term ended Term ended Mar 31, 2026 · High confidence | Term ended | Term ended Mar 31, 2026 | High confidence |
| US 7,879,620 | Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease Term ended Term ended Mar 31, 2026 · High confidence | Term ended | Term ended Mar 31, 2026 | High confidence |
| US 8,097,469 | Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease Term ended Term ended Mar 31, 2026 · High confidence | Term ended | Term ended Mar 31, 2026 | High confidence |